title: Combined androgen blockade may have long term survival benefits over monotherapy, but may increase adverse effects and reduce quality of life in advanced prostate cancer.
authors.affiliation: Department of Urology, Faculty of Medicine, University of Tsukuba, 1-1-1, Tennoudai, Tsukuba City, Ibaraki, Japan. akazah@md.tsukuba.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Akaza